Growth factors in the therapy of myelodisplasia

Biological aspects

Maurizio Bonfichi, Cesare Astori, Emilio Paolo Alessandrino, P. B A Balduini, Carlo Castagnola, Ercole Brusamolino, Guido Pagnucco, Angelo Canevari, Paola Trucco, Carlo Bernasconi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Growth factors (GF) are reported to play an important role in the therapy of myelodisplastic syndromes (MDS). After in vitro administration a consistent group of MDS may respond to GF but the possibility of differentiation, regulation or expansion of myelodisplastic clones following GF therapy is still a question to be answered as their optimum dose and combinations. To validate if in vivo treatment with GF, may promote the regulation or the recovery of myelopoiesis and/or modify the clonality of the responses, we gave G-CSF after intensive chemotherapy in high risk MDS and acute Leukemia evolving from MDS patients. According to our data the use of G-CSF after intensive chemotherapy may improve the CR rate without increase of leukemic transformation. However the answer were clonal and the remission duration remained very short so we suggest to utilize this time to perform other therapeutic strategies such as, when possible, the BMT.

Original languageEnglish
Pages (from-to)35-40
Number of pages6
JournalLeukemia and Lymphoma
Volume26
Issue numberSUPPL. 1
Publication statusPublished - 1997

Fingerprint

Biological Therapy
Intercellular Signaling Peptides and Proteins
Granulocyte Colony-Stimulating Factor
Growth Differentiation Factors
Myelopoiesis
Drug Therapy
Therapeutics
Leukemia
Clone Cells

Keywords

  • Growth factors
  • Myelodisplastic syndromes

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Bonfichi, M., Astori, C., Alessandrino, E. P., Balduini, P. B. A., Castagnola, C., Brusamolino, E., ... Bernasconi, C. (1997). Growth factors in the therapy of myelodisplasia: Biological aspects. Leukemia and Lymphoma, 26(SUPPL. 1), 35-40.

Growth factors in the therapy of myelodisplasia : Biological aspects. / Bonfichi, Maurizio; Astori, Cesare; Alessandrino, Emilio Paolo; Balduini, P. B A; Castagnola, Carlo; Brusamolino, Ercole; Pagnucco, Guido; Canevari, Angelo; Trucco, Paola; Bernasconi, Carlo.

In: Leukemia and Lymphoma, Vol. 26, No. SUPPL. 1, 1997, p. 35-40.

Research output: Contribution to journalArticle

Bonfichi, M, Astori, C, Alessandrino, EP, Balduini, PBA, Castagnola, C, Brusamolino, E, Pagnucco, G, Canevari, A, Trucco, P & Bernasconi, C 1997, 'Growth factors in the therapy of myelodisplasia: Biological aspects', Leukemia and Lymphoma, vol. 26, no. SUPPL. 1, pp. 35-40.
Bonfichi M, Astori C, Alessandrino EP, Balduini PBA, Castagnola C, Brusamolino E et al. Growth factors in the therapy of myelodisplasia: Biological aspects. Leukemia and Lymphoma. 1997;26(SUPPL. 1):35-40.
Bonfichi, Maurizio ; Astori, Cesare ; Alessandrino, Emilio Paolo ; Balduini, P. B A ; Castagnola, Carlo ; Brusamolino, Ercole ; Pagnucco, Guido ; Canevari, Angelo ; Trucco, Paola ; Bernasconi, Carlo. / Growth factors in the therapy of myelodisplasia : Biological aspects. In: Leukemia and Lymphoma. 1997 ; Vol. 26, No. SUPPL. 1. pp. 35-40.
@article{47a94700976c42ca8c38ab469c31fed9,
title = "Growth factors in the therapy of myelodisplasia: Biological aspects",
abstract = "Growth factors (GF) are reported to play an important role in the therapy of myelodisplastic syndromes (MDS). After in vitro administration a consistent group of MDS may respond to GF but the possibility of differentiation, regulation or expansion of myelodisplastic clones following GF therapy is still a question to be answered as their optimum dose and combinations. To validate if in vivo treatment with GF, may promote the regulation or the recovery of myelopoiesis and/or modify the clonality of the responses, we gave G-CSF after intensive chemotherapy in high risk MDS and acute Leukemia evolving from MDS patients. According to our data the use of G-CSF after intensive chemotherapy may improve the CR rate without increase of leukemic transformation. However the answer were clonal and the remission duration remained very short so we suggest to utilize this time to perform other therapeutic strategies such as, when possible, the BMT.",
keywords = "Growth factors, Myelodisplastic syndromes",
author = "Maurizio Bonfichi and Cesare Astori and Alessandrino, {Emilio Paolo} and Balduini, {P. B A} and Carlo Castagnola and Ercole Brusamolino and Guido Pagnucco and Angelo Canevari and Paola Trucco and Carlo Bernasconi",
year = "1997",
language = "English",
volume = "26",
pages = "35--40",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Growth factors in the therapy of myelodisplasia

T2 - Biological aspects

AU - Bonfichi, Maurizio

AU - Astori, Cesare

AU - Alessandrino, Emilio Paolo

AU - Balduini, P. B A

AU - Castagnola, Carlo

AU - Brusamolino, Ercole

AU - Pagnucco, Guido

AU - Canevari, Angelo

AU - Trucco, Paola

AU - Bernasconi, Carlo

PY - 1997

Y1 - 1997

N2 - Growth factors (GF) are reported to play an important role in the therapy of myelodisplastic syndromes (MDS). After in vitro administration a consistent group of MDS may respond to GF but the possibility of differentiation, regulation or expansion of myelodisplastic clones following GF therapy is still a question to be answered as their optimum dose and combinations. To validate if in vivo treatment with GF, may promote the regulation or the recovery of myelopoiesis and/or modify the clonality of the responses, we gave G-CSF after intensive chemotherapy in high risk MDS and acute Leukemia evolving from MDS patients. According to our data the use of G-CSF after intensive chemotherapy may improve the CR rate without increase of leukemic transformation. However the answer were clonal and the remission duration remained very short so we suggest to utilize this time to perform other therapeutic strategies such as, when possible, the BMT.

AB - Growth factors (GF) are reported to play an important role in the therapy of myelodisplastic syndromes (MDS). After in vitro administration a consistent group of MDS may respond to GF but the possibility of differentiation, regulation or expansion of myelodisplastic clones following GF therapy is still a question to be answered as their optimum dose and combinations. To validate if in vivo treatment with GF, may promote the regulation or the recovery of myelopoiesis and/or modify the clonality of the responses, we gave G-CSF after intensive chemotherapy in high risk MDS and acute Leukemia evolving from MDS patients. According to our data the use of G-CSF after intensive chemotherapy may improve the CR rate without increase of leukemic transformation. However the answer were clonal and the remission duration remained very short so we suggest to utilize this time to perform other therapeutic strategies such as, when possible, the BMT.

KW - Growth factors

KW - Myelodisplastic syndromes

UR - http://www.scopus.com/inward/record.url?scp=7144235828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7144235828&partnerID=8YFLogxK

M3 - Article

VL - 26

SP - 35

EP - 40

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - SUPPL. 1

ER -